Why the IL-23/Th17 axis dominates IBD drug development

The IL-23/Th17 immune axis is the most prominently addressed pathway across the current IBD patent dataset — and the genetics explain why. IL-23, a heterodimeric cytokine composed of a unique p19 subunit and a p40 subunit shared with IL-12, activates JAK2/TYK2 and STAT3/STAT4 signalling downstream of the IL-23 receptor (IL-23R), driving differentiation of pathogenic T cell lineages that co-produce IFN-γ, IL-17A, IL-17F, and IL-22. Genome-wide association studies (GWAS) documented in Janssen Biotech patent filings have identified polymorphisms in the IL-23R gene directly associated with IBD risk and protection — providing the genetic rationale that has made this pathway a primary commercial target.

IBD — encompassing Crohn’s disease (CD) and ulcerative colitis (UC) — represents a major unmet medical need affecting an estimated five million patients globally. Current approved therapies fail to sustain remission in 40–50% of initial responders, creating the commercial and scientific pressure driving this pipeline. The disease model retrieved across patent and literature records describes dysregulated Th1 and Th17 helper cell activity driving mucosal immunopathology, with the IL-23 axis as the central pathogenic node.

Three additional upstream targets have emerged alongside IL-23. The TNF-like cytokine 1A (TL1A, encoded by TNFSF15) is identified in multiple patent records as a co-stimulatory driver of Th1, Th2, Th9, and Th17 responses through death receptor 3 (DR3), with GWAS linking TNFSF15 single-nucleotide polymorphisms to refractory UC. Oncostatin-M (OSM) and its receptor OSMR-β — identified in an Oxford University Innovation patent — are highly expressed in IBD intestinal mucosa during active disease, with expression correlating with disease severity across at least four mouse colitis models. The TGF-β/SMAD7 axis constitutes a third mechanistic node: SMAD7 suppresses TGF-β1 signalling and thereby amplifies mucosal inflammation, with anti-SMAD7 antisense oligonucleotides proposed to restore mucosal immune tolerance.

Additional targets present across retrieved results include IL-17A, IL-17F, IL-6, fibronectin ED-A isoform as a mucosal tissue marker, and integrin α4β7. According to WHO global disease burden data, chronic inflammatory conditions including IBD represent an increasing share of non-communicable disease morbidity in both high- and middle-income countries, underscoring the scale of the unmet need this pipeline is addressing.

The six therapeutic modalities reshaping the IBD pipeline

Six distinct therapeutic modalities appear across the retrieved patent and literature dataset, ranging from late-stage clinical biologics to early-stage metabolic immunomodulators — each targeting a different node in the Th17 differentiation and mucosal inflammation cascade.

Anti-IL-23p19 monoclonal antibodies

The most richly represented modality in this dataset is selective blockade of the IL-23 p19 subunit. Patent filings from Janssen Biotech (guselkumab) and Eli Lilly (mirikizumab) describe methods of treating UC and CD using anti-IL-23p19 antibodies, with clinical endpoints including endoscopic remission, histologic healing, and bowel urgency resolution. A Janssen filing covering UC specifically addresses patients unresponsive to prior anti-TNF therapy. An Eli Lilly 2025 CN filing describes pediatric dosing regimens for mirikizumab in UC by weight band — a strong signal of late-stage or post-approval label expansion. Janssen Biotech is the most patent-active assignee in this dataset, with at least six retrieved filings covering guselkumab across CN, JP, MX, and WO jurisdictions.

Anti-TL1A biologics

TL1A inhibition is emerging as the most commercially active next-wave target in the dataset. Four patent records from Prometheus Biosciences (acquired by Merck) and Pfizer describe anti-TL1A antibody approaches that are framed as dual-mechanism agents: TL1A drives both mucosal inflammation and intestinal fibrosis through DR3 signalling in T cells, NK cells, innate lymphoid cells, fibroblasts, and epithelial cells. The fibrosis dimension is commercially significant — 70% of CD patients develop strictures or perforations, and current anti-inflammatory therapies have not meaningfully altered fibrosis rates. Pfizer’s 2023 CN patent describes a specific 12-week induction period followed by maintenance dosing, standard clinical trial language for an active development program. According to NIH research on intestinal fibrosis, no approved therapy currently reverses established stricturing in CD — a gap that anti-TL1A approaches are explicitly positioned to address.

Anti-SMAD7 antisense oligonucleotides

Two patent records from Celgene Alpine Investment Company II (previously Nogra Pharma) describe SMAD7 ASO-based IBD treatment. SMAD7 suppresses TGF-β1 signalling, amplifying mucosal inflammation; ASO-mediated knockdown is proposed to restore TGF-β1 activity and promote regulatory T cell (Treg) function. The patents describe multi-phase dosing regimens and biomarker monitoring using CCL20, IL-8, TNFα, CRP, IL-6, IL-12, and HLA-DR, with patient selection based on Crohn’s Disease Activity Index (CDAI) scores. The inactive legal status of some filings in JP and CN jurisdictions may reflect the known clinical history of oral mongersen, though the dataset does not confirm this directly.

IL-17A and IL-17F pathway antagonists

Multiple retrieved records address IL-17 family cytokines as downstream effectors of the Th17 axis. Wyeth (now Pfizer) filings document increased IL-17F mRNA in UC and CD patient tissue. An Amgen anti-IL-17RA antigen-binding protein patent describes blocking both IL-17A and IL-17F signalling via the shared receptor. A Tsinghua University patent introduces IL-17D and its receptor CD93 as a novel cytokine-receptor pair implicated in intestinal homeostasis dysregulation — an earlier-stage mechanistic signal relative to the mature IL-17A/RA clinical programs already approved in psoriasis and ankylosing spondylitis.

Metabolic immunomodulators: the norUDCA mechanism

A retrieved paper from the Medical University of Vienna demonstrates that 24-Nor-ursodeoxycholic acid (norUDCA), a bile acid derivative, rebalances the Th17/Treg ratio by restricting glutaminolysis in differentiating Th17 cells. This suppresses α-ketoglutarate-dependent mTORC1 activation and glycolysis while enhancing FOXP3 expression. These effects were validated in both murine IBD models and circulating CD4+ T cells from primary sclerosing cholangitis (PSC) patients with co-existing IBD — providing a translational bridge between animal and human data. This represents a small-molecule immunometabolic approach acting at a pre-cytokine metabolic checkpoint, distinct from all biologic modalities.

“Upstream Th17 suppression via metabolic reprogramming — restricting glutaminolysis to suppress mTORC1 — represents an under-patented mechanistic niche relative to the antibody space, potentially offering differentiated IP positioning for developers willing to pursue non-biologic modalities targeting T cell fate commitment rather than secreted cytokines.”

OSM/OSMR antagonism

Oxford University Innovation Limited’s patent identifies OSM as a component of the Th17 induction pathway highly expressed in IBD intestinal mucosa, with expression correlating with disease severity. Systemic OSM administration worsens murine colitis across at least four mouse models, while therapeutic blockade or genetic deletion of OSM ameliorates immunopathology. This positions OSM antagonism as an early but potentially differentiating upstream Th17 suppression strategy — one with a limited current patent footprint relative to IL-23 and TL1A.

Combination regimens: the field’s next competitive frontier

The IBD pipeline is moving toward mechanistic complementarity rather than sequential monotherapy, with patent coverage of dual-biologic combinations increasingly filed before Phase 3 readouts — creating IP thickets that will affect biosimilar and combination product development timelines.

The most developed combination approach in the dataset is IL-23 + TNFα dual blockade. Multiple Janssen Biotech patent records across CN, JP, MX, and WO jurisdictions describe combining anti-IL-23p19 (guselkumab) with anti-TNFα (golimumab) for UC and CD, specifically targeting patients who fail either agent as monotherapy. The strategic rationale explicitly addresses the subset of non-responders to TNFα or IL-23 inhibition alone — a population that represents a substantial commercial opportunity given the 40–50% remission failure rate on current therapies.

Prometheus Biosciences (Merck) has filed a CN patent describing simultaneous administration of a TL1A inhibitor and an IL-23 inhibitor, with sequential maintenance using either agent alone. The filing explicitly states that IL-23 is “one of the key facilitators” of the Th17 pathway and that combined blockade provides synergistic benefits. The patent lists multiple IL-23 inhibitors as combination partners — ustekinumab, guselkumab, risankizumab, blaizumab, mirikizumab, brazikumab, and briakinumab — signalling an intent to claim broad combination coverage across the IL-23 inhibitor class.

Takeda’s 2025 WO filing describes a third combination axis: vedolizumab (anti-α4β7 integrin) combined with JAK inhibitors, using tight junction protein expression (CLDN3, OCLN, TJP1) as molecular markers of mucosal barrier restoration. This approach combines mucosal trafficking blockade with intracellular cytokine signal suppression — and uses biomarker evidence of synergistic mucosal healing as the mechanistic differentiator. A Schering Corporation (Merck) CN patent also describes a sequential regimen in which a pro-inflammatory cytokine antagonist provides acute symptom relief while IL-23 blockade sustains long-term Th17 suppression.

Mucosal healing biomarkers as a competitive IP strategy

Companion diagnostic co-development is transitioning from a regulatory requirement to a competitive IP strategy in the IBD pipeline — developers without biomarker-linked claims may face commercial disadvantages in payor and prescriber adoption even if their compounds achieve efficacy endpoints.

CCL20 has emerged as a dual-function biomarker across two distinct mechanistic contexts. An Amgen patent describes CCL20 as a predictive biomarker for clinical response to anti-IL-23 therapy, combinable with IL-22 and lipocalin-2 (LCN2) for patient stratification in CD and UC. Separately, CCL20 is identified in Celgene SMAD7 ASO monitoring patents as a downstream pathway biomarker tracked alongside IL-8, TNFα, CRP, IL-6, IL-12, and HLA-DR. This dual role positions CCL20 as a cross-modality stratification tool.

Tight junction proteins CLDN3, OCLN, and TJP1 are incorporated as mucosal healing markers in Takeda’s vedolizumab + JAK inhibitor patent — translating molecular evidence of epithelial barrier restoration into a patent claim. Nestlé (Société des Produits Nestlé S.A.) holds a series of patent records describing mucosal healing index determination from multi-timepoint biomarker arrays during anti-TNF therapy, establishing a translational tool for therapeutic management. GWAS-linked SNPs in TNFSF15 are cited in Prometheus Biosciences filings as patient stratification tools for anti-TL1A therapy — a genotype-based precision medicine positioning strategy.

According to standards published by EMA on companion diagnostics, regulatory agencies increasingly expect biomarker-based patient selection evidence to accompany biologic approval applications — reinforcing the commercial rationale for incorporating biomarker claims into the core patent estate rather than treating them as supplementary filings.

Strategic implications for developers and IP teams

The IBD patent landscape described in this dataset carries five distinct strategic implications for drug developers, IP counsel, and R&D leaders evaluating entry or expansion in this space.

Freedom-to-operate analysis is essential for any new anti-IL-23p19 entrant. Janssen Biotech, Eli Lilly, and Amgen hold overlapping but non-identical claims covering monospecific antibodies, gene expression profiling for patient stratification, and biomarker-guided dosing across multiple jurisdictions. The volume and jurisdictional breadth of Janssen’s filings — at least six retrieved records across CN, JP, MX, and WO — signal an active life cycle management and combination strategy program that new entrants must navigate carefully. According to WIPO patent analytics on biopharmaceutical IP concentration, antibody-based biologics targeting shared cytokine pathways represent some of the most densely filed technology spaces in the pharmaceutical sector.

TL1A inhibition is the most commercially active next-wave target. Prometheus Biosciences (Merck) is constructing a multi-layered IP estate spanning antibody compositions, genotype-based patient selection, combination regimens, and companion diagnostics — a precision medicine positioning strategy that differentiates from cytokine-only approaches by incorporating fibrosis as a co-endpoint. This architecture suggests Merck is building toward a companion diagnostic co-approval model rather than a broad-label biologic strategy.

Upstream metabolic and ASO approaches represent under-patented niches. Upstream Th17 suppression via metabolic reprogramming (norUDCA, mTORC1/glutaminolysis axis) and ASO-based SMAD7 knockdown remain under-patented relative to the antibody space. For developers willing to pursue non-biologic modalities targeting T cell fate commitment rather than secreted cytokines, these niches may offer differentiated IP positioning and potentially cleaner freedom-to-operate landscapes.

OSM/OSMR antagonism is an early-stage differentiating opportunity. Oxford University Innovation’s patent on OSM as a first-time-described component of the Th17 induction pathway in IBD represents a mechanistically novel upstream target with a limited current patent footprint. The four-model murine validation and disease severity correlation data provide a scientific foundation, but clinical translation signals are not yet present in the retrieved dataset.

Combination therapy IP must be filed early. The pattern of dual-biologic combination patents being filed before Phase 3 readouts — observed across Janssen, Prometheus/Merck, and Takeda — signals that IP strategy in IBD is increasingly anticipatory rather than reactive. Developers who delay combination therapy filings until after clinical proof-of-concept risk finding the space already claimed by larger incumbents.